STOCK TITAN
  1. Home
  2. News
  3. MTNB

Matinas Biopharma Holdings Inc - MTNB STOCK NEWS

Welcome to our dedicated news page for Matinas Biopharma Holdings (Ticker: MTNB), a resource for investors and traders seeking the latest updates and insights on Matinas Biopharma Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Matinas Biopharma Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Matinas Biopharma Holdings's position in the market.

News
Matinas BioPharma Prices $10 Million Registered Direct Offering
Rhea-AI Summary
Matinas BioPharma Holdings, Inc. (MTNB) announces a registered direct offering of common stock and warrants to institutional investors, raising approximately $10 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-35%
Tags
offering
-
News
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
Rhea-AI Summary
Matinas BioPharma Holdings, Inc. reports 2023 financial results and progress on the ORALTO Phase 3 trial for MAT2203. The company aims to address severe invasive fungal infections with potential new treatment paradigms. Successful Compassionate/Expanded Use Access Program and advancements in the LNC platform demonstrate promising results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.52%
Tags
earnings
-
News
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
Rhea-AI Summary
Matinas BioPharma Holdings, Inc. (MTNB) announces positive results from an in vivo study showing that oral LNC-docetaxel reduces toxicity compared to IV-docetaxel, with no weight loss observed in mice. The study highlights the potential of LNCs for targeted drug delivery in oncology applications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.39%
Tags
none
News
Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response
Rhea-AI Summary
Matinas BioPharma announces complete clinical response in patients with invasive fusarium infection treated with MAT2203, showing promising results in difficult-to-treat cases. The oral formulation of amphotericin B demonstrated effectiveness in patients with treatment options, paving the way for the upcoming Phase 3 trial for invasive aspergillosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.43%
Tags
none
-
News
Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards
Rhea-AI Summary
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) has successfully resolved the low selling price deficiency, regaining compliance with NYSE American's listing standards. The Company's common stock showed sustained price improvement, leading to the removal of the noncompliant status.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.43%
Tags
none
-
News
Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution
Rhea-AI Summary
Matinas BioPharma (MTNB) provides a positive update on its Compassionate/Expanded Use Access Program with MAT2203, showing promising results in treating invasive fungal infections. Out of 19 patients enrolled, those completing treatment had complete clinical resolution, with significant improvements seen in others. MAT2203 demonstrated efficacy in patients with limited treatment options, addressing a significant medical need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.55%
Tags
none
News
Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis
Rhea-AI Summary
Matinas BioPharma announces alignment with the FDA on the design of a Phase 3 trial for MAT2203 in patients with invasive aspergillosis. The trial aims to provide a step-down treatment option for adults with limited or no treatment choices, focusing on all-cause mortality and treatment-related toxicities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.91%
Tags
clinical trial
-
News
Matinas BioPharma to Present at Biotech Showcase 2024
Rhea-AI Summary
Matinas BioPharma (NYSE American: MTNB) announces CEO Jerome D. Jabbour will present a company overview at the Biotech Showcase 2024. The presentation will be available via webcast on the company's website. Institutional investors can schedule meetings with management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.78%
Tags
conferences
-
News
Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides
Rhea-AI Summary
Matinas BioPharma Holdings, a clinical-stage biopharmaceutical company (NYSE American: MTNB), reports successful oral delivery of LNC-formulated small single-strand oligonucleotides targeting key inflammatory cytokines TNFα and IL-17A in acute colitis and psoriasis models, showing significant reductions in serum TNFα levels and tissue IL-17A mRNA, with improvements in clinical disease markers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.3%
Tags
none
News
Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA
Rhea-AI Summary
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) receives positive feedback from FDA on Phase 3 study design for MAT2203, moving closer to full alignment with FDA. Partnership discussions ongoing. Meeting with FDA planned in early 2024 to finalize Phase 3 protocol.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
none
Stock MTNB logo
Matinas Biopharma Holdings Inc

NYSE:MTNB

MTNB Rankings

#4787 Ranked by Market Cap
#5182 Ranked by Stock Gains
N/A Ranked by Dividends

MTNB Stock Data

50.97M
211.96M
2.53%
10.43%
1.51%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Bedminster

About MTNB

matinas biopharma (nyse mkt: mtnb) is a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications. the company's proprietary, disruptive technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, making them safer, more tolerable, less toxic and orally bioavailable. the company's lead drug candidate mat2203, currently in phase 2, is an orally-administered, encochleated formulation of amphotericin b (a broad spectrum fungicidal agent). the company has an open investigational new drug (ind) application for mat2501, currently in phase 1, which is an orally-administered, encochleated formulation of amikacin (a broad spectrum aminoglycoside antibiotic agent) for acute bacterial infections, including non-tuberculous mycobacterium (ntm) and multi-drug resistant gram negative bacterial infections. the company's lead anti-infective product candidates, mat2203 and mat2501, position matinas biopharma to bec